Optimizing Allergy & Asthma Biologic Programs: Best Practices for Providers

What to Know

• Optimizing biologic programs starts with accurate patient phenotyping, clear workflows, and active follow-up.
• In-office biologic therapy through Altus Biologics improves adherence, convenience, and overall patient experience.
• Multidisciplinary collaboration among allergists, pulmonologists, and primary care providers ensures each patient receives the most appropriate biologic therapy, precisely when it’s needed.
• Tracking outcomes such as exacerbation rates, oral corticosteroid use, and quality-of-life measures helps demonstrate program success and guides adjustments.
• A strong partnership with Altus Biologics provides the infrastructure, training, and operational support needed to make biologic therapy seamless for providers and patients alike.

The Importance of Optimizing Allergy & Asthma Biologic Programs

Biologic therapies have transformed the care landscape for patients living with moderate-to-severe asthma and allergic diseases.

Yet, success depends on more than prescribing the appropriate medication; it requires a coordinated, patient-centered program that blends clinical precision with operational excellence.

At Altus Biologics, we partner with providers nationwide to simplify in-office biologic therapy, helping practices deliver these advanced treatments safely, efficiently, and compassionately.

The following best practices are designed to help your team refine biologic program performance, enhance clinical outcomes, and create a more seamless, patient-centered experience.

Laying the Foundation: Patient Selection and Phenotyping

Define Clear Eligibility Criteria

An effective biologic program begins with the right patients.

Develop standardized criteria for identifying candidates who continue to experience uncontrolled asthma or allergic disease despite optimized therapy.

Typical indicators include:

• Two or more exacerbations or hospitalizations in the past year
• Frequent oral corticosteroid (OCS) bursts or SABA overuse
• Elevated biomarkers (eosinophils, FeNO, or IgE)
• Coexisting allergic rhinitis or atopic dermatitis

Having consistent criteria promotes fair, evidence-based selection and streamlines referrals between your team and collaborating specialists.

Match the Biologic to the Phenotype

Each biologic targets a specific pathway, so aligning the therapy with the patient’s phenotype is essential. Consider inflammatory profile, comorbidities, administration preference, and prior response history. This precision-based approach improves both outcomes and cost-effectiveness.

Once the optimal therapy is selected, seamless delivery and follow-up are key to success. At Altus Biologics, we support practices with in-office administration, enabling you to deliver biologics under clinical supervision and track results in real time.

Optimize Before You Initiate

With patient selection and biologic matching complete, preparation becomes the next critical step in achieving consistent outcomes.

Ensure modifiable factors are addressed before initiating therapy. Review inhaler technique, reinforce adherence, manage environmental triggers, and address comorbidities such as obesity or sleep apnea. Setting this foundation helps ensure biologic therapy delivers its full benefit.

Integrating Biologic Therapy into Your Practice

Build a Streamlined Workflow

From screening to administration, efficient workflows reduce delays and ensure safety.

Key components include:

• Clear clinical pathways for screening and documentation
• Create designated staff roles for injection visits and follow-up monitoring
• Clearly define protocols for managing adverse events
• Partner with Altus Biologics for supply, reimbursement support, and patient scheduling

A structured process keeps your program running smoothly and instills confidence in patients.

Educate and Empower Patients

Education builds trust and adherence.

Review how the biologic works, expected timelines, injection frequency, and possible side effects. Encourage patients to continue their baseline therapies and follow an individualized action plan.

Patients who understand their therapy are more engaged and consistent, two key predictors of long-term success.

Track Data from Day One

Collect baseline data on exacerbation frequency, lung function, biomarkers, and quality-of-life scores before treatment begins.

Then reassess at 4–6 months and again at 12 months.

With in-office administration, you can conveniently track and adjust therapy based on objective metrics; something Altus Biologics helps facilitate through streamlined reporting tools and continuous staff training.

Monitoring Response and Sustaining Success

Define Response Benchmarks

Establish what “success” means for each patient: fewer exacerbations, improved FEV₁, or reduced OCS dependence.

Evaluate at regular intervals:

• 4–6 months: initial response and adherence check
• 12 months: comprehensive assessment and long-term planning

If the response is suboptimal, review adherence, environmental exposures, or consider switching to a biologic with a different mechanism of action.

Support Adherence and Continuity

Ongoing engagement is vital. Regular injection visits, follow-up calls, and patient reminders help maintain consistency.

Encourage open communication so patients can share any challenges early, allowing you and your team to intervene before control declines.

Plan for Safety, Cost-Effectiveness, and De-escalation

Biologics are generally well tolerated, but regular monitoring for side effects and periodic reassessment of therapy needs are essential.

Document improvements in control, quality of life, and healthcare utilization; these metrics help demonstrate value to payers and justify continued therapy.

Collaboration and Growth

Strengthen Your Network

A thriving biologic program depends on teamwork. Collaborate closely with primary-care providers, allergists, and pulmonologists to ensure seamless referrals and coordinated care.

Share outcome data and patient progress updates, as this helps to strengthen trust across the network and enhances your program’s visibility.

Altus Biologics helps practices create cohesive workflows between referring providers, offering guidance on patient onboarding, documentation, and follow-up communication.

Promote Awareness of Your Program

• Let your community know about your in-office biologic therapy offerings.
• Share success stories and patient improvements (with consent).
• Educate referring physicians on referral criteria.
• Highlight the convenience and continuity of care your in-office biologic suite provides.

These steps position your practice as a trusted destination for advanced allergy and asthma management.

Delivering Better Outcomes Through Optimized Biologic Care

Optimizing an allergy and asthma biologic program means combining clinical excellence, operational efficiency, and compassionate care.

By standardizing patient selection, creating seamless workflows, and tracking measurable outcomes, you can deliver life-changing therapies while strengthening your practice’s reputation and reach.

At Altus Biologics, we’re here to make that possible, helping you bring advanced biologic therapy directly to your patients in a safe, comfortable, and familiar setting.

Together, we can transform how allergy and asthma care is delivered, one patient at a time.

FAQ

Q: When should I consider a patient for biologic therapy?

A: When a patient remains uncontrolled despite high-dose inhaled therapy, frequent OCS use, or multiple exacerbations within a year, it’s time to assess eligibility for biologic therapy.

Q: How long does it take to see results from a biologic therapy?

A: Each patient’s response to biologic therapy is different; however, in many cases, initial improvements are often seen within 4–6 months, but a complete response assessment is recommended at 12 months, including symptom control, biomarker changes, and exacerbation frequency.

Q: Can biologic therapy be safely administered in a private practice?

A: Yes. With the proper infrastructure and monitoring protocols, in-office biologic administration is both safe and effective. Altus Biologics provides turnkey support to implement this model.

Q: What data should I track to measure the biologic infusion program’s success?

A: Track exacerbation rates, OCS reduction, SABA use, lung function, and patient-reported outcomes to evaluate effectiveness and ensure ongoing improvement.

Q: What if a patient doesn’t respond to the first biologic?

A: When a patient does not respond to the first biologic prescribed, treating physicians must review adherence, address modifiable factors, and, if needed, consider switching to another biologic class aligned with the patient’s phenotype.

Q: How can biologic programs improve clinic efficiency?

A: In-office biologic therapy centralizes treatment and monitoring, reducing fragmentation of care while enhancing adherence, patient satisfaction, and operational control.

Q: Why partner with Altus Biologics to offer in-office biologic therapy?

A: At Altus Biologics, we provide complete in-office biologic management solutions, including staffing, training, supply logistics, and reimbursement support, so your team can focus on what matters most: delivering excellent patient care.